Company Filing History:
Years Active: 2014
Title: Arama Albisa Novo: Innovator in Vaccine Development
Introduction
Arama Albisa Novo is a notable inventor based in Havana, Cuba. He has made significant contributions to the field of vaccine development, particularly in the treatment of tumors. His innovative approach has the potential to enhance therapeutic options for cancer patients.
Latest Patents
Arama holds a patent for a "Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors." This vaccine composition is designed for therapeutic use in cancer patients and includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k. The conjugation reaction produces this chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases immunogenic activity, leading to significant increases in anti-EGF antibody titers in humans. This innovative vaccine preparation offers more than one type of effective dose presentation, allowing for an increased immunization dose per patient without raising the frequency of immunizations or the number of immunization sites.
Career Highlights
Arama is affiliated with the Centro de Inmunología Molecular (CIM), where he continues to work on groundbreaking research in immunology and vaccine development. His dedication to advancing medical science is evident in his innovative patent and ongoing research efforts.
Collaborations
Arama collaborates with talented individuals in his field, including Gryssell Rodriguez Martinez and Lisel Vina Rodriguez. Their teamwork contributes to the success of their research initiatives and the development of effective vaccine solutions.
Conclusion
Arama Albisa Novo's work in vaccine development represents a significant advancement in cancer treatment. His innovative methods and collaborative efforts are paving the way for improved therapeutic options for patients.